Related Experiment Video
Updated: May 23, 2025
Author Spotlight: Unraveling Vitamin A Transport Mechanisms — Linking Liver Receptors to Vision Health Through RBPR2 and RBP4 Interactions
Published on: October 4, 2024
Retinoid X Receptor as a Therapeutic Target to Treat Neurological Disorders Associated with α -Synucleinopathy
Abstract:
This study investigated the therapeutic potential of the nuclear retinoid X receptor (RXR) in mitigating the progression of alpha-synucleinopathies (αSNPs), particularly in Parkinson's disease (PD). PD-like pathology in mice was successfully induced through the co-delivery of AAV expressing human α-synuclein (αS) and αS preformed fibrils (PFFs) into the substantia nigra pars compacta (SNpc). Significant increases in Lewy body (LB)-like inclusions, loss of tyrosine hydroxylase-positive (TH+) neurons, and reductions in dopamine (DA) levels in the striatum were observed. Additionally, diminished levels of PPARα and NURR1, along with elevated GFAP and Iba1, markers of neuroinflammation, microglial activation, and astrocytic gliosis were associated with PD pathogenesis. AAV-mediated overexpression of human RXRα demonstrated preservation of TH+ neurons, prevention of DA decline and attenuation of αS accumulation. Furthermore, RXR-treated PD brains showed a reduced number of GFAP+ and Iba1+ cells, decreased GFAP+ and Iba1+ immunoreactivity, and fewer and less widespread LB-like aggregates. RXR overexpression also enhanced the production of PPARα and NURR1, proteins critical for neuronal survival. These findings suggest that RXRα activation promotes neuroprotection by mitigating αSNPs and chronic neuroinflammation, a major contributor to PD progression. This research underscores the therapeutic potential of targeting nuclear receptors, such as RXR, in neurodegenerative diseases like PD.
Insights
Nuclear Retinoid X Receptor (RXR) activation shows therapeutic potential for Parkinson's disease (PD) by reducing alpha-synuclein pathology and neuroinflammation. This approach offers a promising strategy for treating neurodegenerative disorders.
Area of Science:
- Neuroscience
- Molecular Biology
- Pharmacology
Background:
- Alpha-synucleinopathies (αSNPs), like Parkinson's disease (PD), are characterized by protein aggregation and neuroinflammation.
- Nuclear receptors, such as the Retinoid X Receptor (RXR), play crucial roles in cellular regulation and have emerged as potential therapeutic targets.
Purpose of the Study:
- To investigate the therapeutic efficacy of nuclear Retinoid X Receptor (RXR) in mitigating alpha-synucleinopathies (αSNPs) and Parkinson's disease (PD) pathology.
- To explore the impact of RXR activation on neuroinflammation, neuronal survival, and alpha-synuclein aggregation in a PD mouse model.
Main Methods:
- A mouse model of PD was established using adeno-associated virus (AAV) vectors to deliver human alpha-synuclein (αS) and preformed fibrils (PFFs) into the substantia nigra pars compacta (SNpc).
- RXR alpha (RXRα) was overexpressed via AAV in PD model mice to assess its protective effects.
- Evaluated markers included Lewy body (LB)-like inclusions, tyrosine hydroxylase-positive (TH+) neurons, dopamine (DA) levels, neuroinflammatory markers (GFAP, Iba1), and proteins like PPARα and NURR1.
Main Results:
- RXRα overexpression preserved TH+ neurons, prevented dopamine decline, and reduced αS accumulation in the PD mouse model.
- RXR treatment significantly decreased markers of neuroinflammation (GFAP, Iba1) and microglial activation.
- RXR activation enhanced levels of PPARα and NURR1, crucial for neuronal survival, and reduced the burden of LB-like aggregates.
Conclusions:
- RXRα activation confers neuroprotection against αSNPs and PD pathogenesis by mitigating alpha-synuclein aggregation and chronic neuroinflammation.
- Targeting nuclear receptors like RXR represents a promising therapeutic strategy for neurodegenerative diseases, including Parkinson's disease.
- RXR activation modulates key pathways involved in neuronal survival and inflammatory responses, highlighting its therapeutic potential.
